Commentary on Mehrotra S,………, McInnes IB, Pharmacological Characterization of Zasocitinib (TAK-279): An Oral, Highly Selective and Potent Allosteric TYK2 Inhibitor, The Journal of Investigative Dermatology (2025), doi: https://doi.org/10.1016/j.jid.2025.05.014.
a) Rationale, Objectives, and Novelty
The rationale for the Mehrotra et al. study stems from the persistent unmet needs in treating immune-mediated inflammatory diseases (IMIDs), such as psoriasis and psoriatic arthritis, despite advancements in therapeutic options. While biologic therapies offer efficacy, they are limited by the need for parenteral administration, potential immunogenicity, and a gradual loss of efficacy. Oral Janus Kinase (JAK) inhibitors, while more convenient, suffer from a broader inhibitory profile, targeting multiple JAK family members (JAK1, JAK2, JAK3, and TYK2). This pan-JAK inhibition leads to various adverse events, including hematologic and lipid abnormalities, increased infection risk, and major adverse cardiovascular events (MACE), due to interference with crucial physiological cytokine signaling pathways. Even more selective JAK1 inhibitors, such as upadacitinib, bind to the highly conserved ATP-binding site within the catalytic Janus homology 1 (JH1) domain, a common feature among many kinase inhibitors.
Within this context, TYK2 has emerged as a particularly strategic therapeutic target. TYK2 is a non-receptor tyrosine kinase that plays a critical role in transducing signals for specific pro-inflammatory cytokines, including IL-23, Type I IFNs, and IL-12, all implicated in IMID pathogenesis. The rationale for targeting TYK2 is further supported by human genetics, where loss-of-function single-nucleotide polymorphisms (SNPs) in the TYK2 gene, such as P1104A, are associated with a protective effect against IMIDs without an increased risk of malignancies, major adverse cardiovascular events (MACE), or severe infections. This provides strong genetic validation for the selective inhibition of TYK2. The development of allosteric TYK2 inhibitors, such as deucravacitinib, which bind to the regulatory pseudokinase (JH2) domain of TYK2, represents a significant breakthrough, offering high selectivity over other JAKs due to the distinct nature of the JH2 domain.
The primary objective of the Mehrotra et al. study was to meticulously evaluate the inhibitory potency and selectivity of zasocitinib for TYK2. A key component of this objective was to directly compare its pharmacological profile with that of the licensed allosteric TYK2 inhibitor, deucravacitinib, as well as a panel of licensed orthosteric JAK inhibitors with varying selectivity profiles: baricitinib (JAK1/JAK2), upadacitinib (predominantly JAK1), and tofacitinib (pan-JAK). Zasocitinib (TAK-279) is presented as a novel oral, allosteric TYK2 inhibitor that, like deucravacitinib, binds to the TYK2 JH2 domain to lock the enzyme in an inactive conformation and block downstream pro-inflammatory signaling. Its novelty and innovation lie in its discovery process, which notably employed an artificial intelligence (AI)-assisted computational design tool for candidate screening, optimizing for high potency for TYK2 JH2 domain binding while eliminating those with suboptimal selectivity profiles.
The most striking claim is its reported biochemical selectivity of more than 1 million-fold for the TYK2 JH2 domain over JAK1 JH2, based on an inhibitory constant (Ki) of 0.0087 nM for TYK2 JH2, with no detectable binding to JAK1 JH2 at concentrations up to 15,000 nM. This level of selectivity is substantially higher than the 87-fold selectivity reported for deucravacitinib in the same HTRF assay conducted in this study.
The million-fold TYK2 JH2 specificity is critical for several reasons:
Minimizes Off-Target Effects: Drastically reduces inhibition of other JAKs (JAK1, JAK2, JAK3) involved in essential physiological functions, thus lowering risks of side effects like blood abnormalities or infections.
Enhances Therapeutic Index: Allows potent TYK2 inhibition without broad JAK interference, potentially improving the efficacy-to-safety ratio.
Validates Allosteric Mechanism: Confirms the advantage of targeting the distinct JH2 pseudokinase domain for highly selective TYK2 blockade.
"Next-Generation" Potential: Positions zasocitinib for a cleaner, more refined pharmacological profile, potentially offering a safer and more robust therapeutic option for IMIDs.
This substantial increase in selectivity, coupled with projections for sustained 24-hour target coverage without measurable impact on other JAKs, positions zasocitinib as a potentially next-generation TYK2 inhibitor.
b) Methodology and Innovations
The pharmacological characterization of zasocitinib by Mehrotra et al. employed a rigorous series of established and contemporary methodologies to delineate its binding affinity, cellular potency, selectivity, and projected pharmacodynamic profile.
Binding Affinity and Biochemical Selectivity: The investigators utilized Homogeneous Time-Resolved Fluorescence (HTRF) assays to determine inhibitory constants (Ki) for zasocitinib and deucravacitinib against recombinant human TYK2 JH2 and JAK1 JH2 domains. HTRF is a robust, widely accepted proximity-based assay suitable for high-throughput studies of molecular interactions. The direct comparison of both TYK2 inhibitors within the same assay system enhances the reliability of the relative biochemical selectivity assessment.
Cellular Potency and Selectivity in Human Whole Blood: To assess functional activity in a more physiologically relevant context, a panel of human whole blood assays was employed. These assays measured the inhibition of TYK2-dependent signaling (e.g., IL-23-induced phosphorylation of Signal Transducer and Activator of Transcription 3 (pSTAT3), Type I IFN-induced pSTAT3, IL-12-induced pSTAT4, and IL-12/IL-18-induced IFN-γ production) and JAK-dependent signaling (e.g., IL-2-induced pSTAT5 for JAK1/JAK3, and thrombopoietin (TPO)-induced pSTAT3 for JAK2) to assess TYK2 selectivity. Phosphorylated STAT proteins were quantified using flow cytometry, a standard technique, and IFN-γ production by ELISA. The use of whole blood is a significant methodological strength, as it accounts for factors such as plasma protein binding and cellular uptake, which influence in vivo drug activity.
Pharmacokinetic/Pharmacodynamic (PK/PD) Modeling and Simulation: To bridge in vitro findings to potential clinical scenarios, PK/PD modeling was performed. This involved generating simulated plasma concentration-time profiles for zasocitinib and comparator drugs at their clinically relevant doses, utilizing published population pharmacokinetic models for the comparators and internal Phase 1 and 2 data for zasocitinib. These simulations were integrated with in vitro half-maximal inhibitory concentration (IC50) and 90% maximal inhibitory concentration (IC90) data derived from whole-blood assays to predict pharmacodynamic parameters, such as the duration of target coverage (T > IC50/T > IC90) and overall daily inhibition over a 24-hour dosing interval. This modeling approach is a standard translational tool in the drug development process.
The methodological approach demonstrates several strengths and innovations. The inclusion of deucravacitinib as a direct allosteric TYK2 inhibitor comparator, alongside diverse orthosteric JAK inhibitors, provides comprehensive contextualization. Direct head-to-head comparisons, particularly for biochemical selectivity and cellular pathway inhibition under identical conditions, enhance the reliability of comparative conclusions. The specific assessment of JH2 domain binding directly interrogates the intended allosteric mechanism of action and is crucial for distinguishing zasocitinib from orthosteric inhibitors. The use of human whole blood assays provides a more physiologically relevant environment than purified enzymes or isolated cell lines, as it better reflects potential in vivo drug behavior. Furthermore, the quantitative PK/PD modeling, which integrates in vitro potency with clinical pharmacokinetic simulations, moves beyond static IC50 values to estimate the consistency and extent of target modulation over a dosing interval, a valuable translational innovation. This alignment with best practices in kinase inhibitor characterization, emphasizing broad selectivity profiling and mechanistic understanding, contributes to the robustness of the study.
c) Conclusion, Importance, and Caveats
From my perspective as a medical researcher accustomed to scrutinizing preclinical data, the pharmacological profile of zasocitinib, as presented by Mehrotra and colleagues, is indeed thought-provoking and warrants careful consideration.
Compelling Aspects of Zasocitinib's Preclinical Profile:
What I find particularly compelling is the remarkable degree of biochemical selectivity that Zasocitinib is reported to possess for the TYK2 JH2 domain.
A selectivity margin of over one million-fold when compared to the JAK1 JH2 domain is, by any measure, a striking achievement in kinase inhibitor design.
While we must always exercise caution in extrapolating biochemical figures directly to complex in vivo scenarios and ultimate clinical outcomes, this level of specificity observed at the initial molecular interaction level is undeniably impressive.
Furthermore, the consistency of zasocitinib's cellular selectivity, as demonstrated in the human whole blood assays, is noteworthy.
The data indicating that zasocitinib, at projected clinical plasma concentrations resulting from a 30 mg once-daily dose, can provide 24-hour coverage of TYK2 IC50 and, for key pathways like IL-23, Type I IFN, and IL-12 signaling, even IC90 coverage, all without any measurable inhibition of JAK1, JAK2, or JAK3 signaling pathways, paints a picture of a highly targeted therapeutic agent.
This projected sustained and exquisitely selective engagement of TYK2 is, in my opinion, a critically important attribute for an oral immunomodulator intended for chronic administration in patients with IMIDs.
Potential Importance of These Findings for IMID Therapeutics:
If these meticulously characterized preclinical attributes of zasocitinib translate effectively into the clinical arena, this agent could represent a significant advancement in the treatment of IMIDs.
The authors define zasocitinib as a "next-generation TYK2 inhibitor", and based on the presented selectivity data and the projected pharmacodynamic profile, I believe this assertion holds considerable merit.
The potential to achieve a robust and continuous blockade of pathogenic TYK2-mediated cytokine signaling, while avoiding the pathways governed by other JAK family members, could theoretically result in an improved benefit-risk profile.
This improvement might be observed not only in comparison to the less selective, first-generation JAK inhibitors but also in offering advantages over other selective TYK2 inhibitors currently available or in late-stage development.
For individuals grappling with the chronic burden of IMIDs, this could translate into achieving desired levels of efficacy with a potentially wider safety margin, particularly concerning the adverse events that have been historically associated with broader JAK inhibition.
This body of work reinforces the profound value of precisely targeting specific nodes within complex inflammatory pathways.
It also serves as a testament to how sophisticated drug design methodologies—including, in this case, the application of AI-assisted computational tools—can yield molecules endowed with highly desirable and refined pharmacological properties.
Caveats and Considerations for the Path Ahead:
While I am genuinely optimistic about the potential implied by these preclinical findings, it is incumbent upon us as scientists to maintain a balanced and critical perspective.
The authors of the primary paper themselves conscientiously acknowledge certain limitations inherent in their study.
These include the reliance on in vitro assays and in silico PK/PD simulations.
While these are indispensable tools in preclinical drug development, providing crucial insights and guiding further investigation, the true crucible for any investigational agent is, of course, human clinical trials.
The adage "the proof of the pudding is in the eating" is particularly apt here; the ongoing Phase 3 clinical trials for zasocitinib in psoriasis and psoriatic arthritis will be paramount in definitively establishing its actual clinical efficacy and safety profile.
The high attrition rate of drug candidates as they transition from promising preclinical stages to clinical validation serves as a constant reminder of the complexities involved in drug development, necessitating a degree of humility when interpreting early-stage data, however impressive.
The use of pSTAT phosphorylation as an intermediate surrogate for downstream signaling, while a valid and widely accepted biomarker, is nonetheless an indirect measure of TYK2 pathway modulation.
The ultimate impact on the multifaceted pathophysiology of IMIDs, and critically, on patient-reported outcomes and quality of life, will define zasocitinib's clinical value.
Additionally, the sensitivity of the assays used, particularly in their ability to detect very low levels of potential JAK1/2/3 inhibition, is always a pertinent consideration.
While "no estimable inhibition" is reported for zasocitinib up to high concentrations, understanding the precise limits of detection of these assays is important for a complete interpretation.
From my viewpoint, a pivotal question for the future will be how zasocitinib differentiates itself clinically, not only from the older, broader-acting JAK inhibitors but, more pointedly, from the approved allosteric TYK2 inhibitor, deucravacitinib, and other emerging selective TYK2 inhibitors such as ESK-001.
Will the enhanced biochemical selectivity and the potentially more sustained and profound target coverage demonstrated preclinically by zasocitinib translate into clinically meaningful advantages?
These could manifest as superior efficacy in achieving stringent treatment goals, a more favorable long-term safety profile, or particular benefits in specific patient subpopulations who may be more sensitive to off-target effects or require more consistent pathway inhibition.
The real differentiators will likely emerge from head-to-head comparative clinical trial data or, in their absence, from meticulously compared outcomes from late-stage trials against existing therapeutic options.
The competitive landscape for IMID therapeutics is dynamic and continually evolving.
We must also consider how oral agents like zasocitinib will be positioned within an ever-expanding armamentarium that includes numerous highly effective biologic therapies.
Its ultimate place in treatment algorithms will depend on a confluence of factors, including its confirmed efficacy, safety, patient convenience, and cost-effectiveness.
Will it establish itself as a preferred first-line oral option for certain IMIDs, a valuable alternative for patients who have had an inadequate response or intolerance to biologics, or perhaps find a niche in specific patient profiles where its unique selectivity offers a distinct advantage?
These are questions that can only be answered by comprehensive clinical data and real-world experience.
In conclusion, the pharmacological characterization of zasocitinib by Mehrotra et al. presents a compelling and meticulously documented preclinical case for a highly selective and potent TYK2 inhibitor with a promising pharmacodynamic profile. The data suggest the potential for a refined therapeutic intervention in IMIDs. I, like many in the field, eagerly await the results from the ongoing Phase 3 clinical trials to ascertain if this considerable preclinical promise is fully realized for the tangible benefit of patients living with these challenging diseases.